8 research outputs found
DiaTrend: A dataset from advanced diabetes technology to enable development of novel analytic solutions
Objective digital data is scarce yet needed in many domains to enable
research that can transform the standard of healthcare. While data from
consumer-grade wearables and smartphones is more accessible, there is critical
need for similar data from clinical-grade devices used by patients with a
diagnosed condition. The prevalence of wearable medical devices in the diabetes
domain sets the stage for unique research and development within this field and
beyond. However, the scarcity of open-source datasets presents a major barrier
to progress. To facilitate broader research on diabetes-relevant problems and
accelerate development of robust computational solutions, we provide the
DiaTrend dataset. The DiaTrend dataset is composed of intensive longitudinal
data from wearable medical devices, including a total of 27,561 days of
continuous glucose monitor data and 8,220 days of insulin pump data from 54
patients with diabetes. This dataset is useful for developing novel analytic
solutions that can reduce the disease burden for people living with diabetes
and increase knowledge on chronic condition management in outpatient settings.Comment: 11 pages, 5 figures, 2 table
Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study
Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research
Investigation of novel drug therapy of KG4 for Toxoplasma gondii infections
Toxoplasma gondii is an extremely common parasite of both animals and humans, infecting an estimated up to 40% of the United States human population, but as much as 50% to 80% of the population in much of South America and continental Europe. In a healthy adult, infection with T. gondii generally results in minimal or no clinical symptoms due to a robust immune system efficiently suppressing the active form of the parasite (the tachyzoite stage). Shortly after infection, however, the parasite forms cysts (the bradyzoite stage) to protect itself from the immune system, which allows for reactivation in the event of immune system depression. T. gondii infection has been identified as a leading cause of severe illness amongst immune compromised individuals and pregnant women. Recently, T. gondii has also been recognized as a threat to many animal species, including the Southern Sea Otter off the California coast. Given these global and multi-species health concerns, it is critical that we identify effective methods for treatment and control of T. gondii. To this end, the goal of this study is to investigate the mechanism of action of the novel drug, KG4, against Toxoplasma gondii infection. We will utilize mutagenesis coupled with genomic sequencing techniques to help identify the gene targeted by KG4 to restrict T. gondii growth. Such information will be beneficial not only for the clinical use of this drug in treating patients worldwide for T. gondii infection, but will also progress our understanding of the parasite for future studies
Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells
The pancreatic tumor microenvironment drives deregulated nutrient availability. Accordingly, pancreatic cancer cells require metabolic adaptations to survive and proliferate. Pancreatic cancer subtypes have been characterized by transcriptional and functional differences, with subtypes reported to exist within the same tumor. However, it remains unclear if this diversity extends to metabolic programming. Here, using metabolomic profiling and functional interrogation of metabolic dependencies, we identify two distinct metabolic subclasses among neoplastic populations within individual human and mouse tumors. Furthermore, these populations are poised for metabolic cross-talk, and in examining this, we find an unexpected role for asparagine supporting proliferation during limited respiration. Constitutive GCN2 activation permits ATF4 signaling in one subtype, driving excess asparagine production. Asparagine release provides resistance during impaired respiration, enabling symbiosis. Functionally, availability of exogenous asparagine during limited respiration indirectly supports maintenance of aspartate pools, a rate-limiting biosynthetic precursor. Conversely, depletion of extracellular asparagine with PEG-asparaginase sensitizes tumors to mitochondrial targeting with phenformin